As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.
Discover >Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.
Discover >Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.
Discover >Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.
Discover >The project represents an important step for Genopole in its international goals. It also lays a foundation for European partnerships in genomics.
GEN.ERA is part of the Cluster Go International call of the European program COSME.
It unites Genopole with Italian (Distretto Tecnologico Campania Bioscience), Estonian (Tartu BT Park), and Finnish (Turku Science Park Ltd) clusters, and the East-Netherlands Development Agency.
GEN.ERA’s objective is to construct within a two-year timeline a European inter-cluster strategy to identify promising markets and ease access to them for businesses positioned in the genomics value chain.
By sharing their experiences and constructing a shared strategy for internationalization, the five partners will be able to approach the global market as a single pan-European cluster and thus better support the development of their start-ups and SMEs beyond Europe.
This ambitious project will begin in early May and Genopole’s companies will be invited to contribute to its realization.
By obtaining the European GEN.ERA project, Genopole confirms the momentum of its ecosystem and its determination to grow in international influence. “The competitiveness of our businesses is a major issue,” underlines Acting Director General of Genopole Anne Jouvenceau. “Pertinent accompaniment aimed at future-looking markets is a key to success.”
* Project GEN.ERA : diGital gENomic alliance to Explore new maRket for Acceleration.
Article posted on 14 February 2020
Genopole strengthens its key roles in synthetic biology, biomanufacturing and the bioeconomy, as demonstrates its notable actions carried out this fall on several national and international scenes.
Discover
Genopole's mission to Japan was a great opportunity to extend its international network of investors and corporations in Eastern Asia. It is opening itself to partnerships with foreign start-ups to strengthen the commercial deployment of innovative breakthroughs for regenerative medicine, gene editing and artificial intelligence.
Discover
With more than 41,000 m² of office and lab premises & more than seven hectares of available land tracts, the real estate offer of the Genopole biocluster is actively laying the groundwork for future developments with projects such as GenoLife and Cube.
Discover
Using an AI approach, Genethon has conceived a next-generation vector improving the specificity and safety of gene therapies for muscular dystrophies.
Discover
Protopia, a new, advanced prototyping platform aimed at transforming R&D in biotech sectors, will be a resounding next-step in support for innovative biotech start-ups and businesses. It aims to accelerate project upscaling and preindustrialization while also empowering interdisciplinary partnerships.
Discover
Research performed at LBEPS has resulted in three publications illustrating how a scientific approach to exercise can optimize athletic performance and health.
Discover
Abolis has reached another milestone in its upscaling objectives. Convinced by the pertinence and robustness of its technology, an international consortium of industrials and funders will provide €35 million to the company.
Discover
Genopole was in Chicago on June 17 and 18 for the Future Food Tech conference. Genopole® accompanied three of the biocluster's companies developing more sustainable food: Nutropy, AuraLIP and Onima. This was an opportunity for them to get noticed by major US groups and investors, and to gain an insight into North American market trends.
Discover
The Genopole team at the BIO International Convention in San Diego pursued three main objectives: promote Genopole accompaniment to attract new talent, highlight biocluster companies and gather information on market and regulatory tendencies.
Discover
June 2024- Lambe has demonstrated the ability of an aerolysin nanopore to discriminate enantiomeric forms of peptide biomarkers useful for medical diagnostics.
Discover
Genopole welcomed a Dutch delegation of close to 20 company representatives and alternative proteins researchers. The objective of the visit was to explore possibilities for research and business partnerships aimed at the development of new foods capable of meeting the future's nutritional, environmental, health, business and gustatory demands.
Discover
With its two new Atige laureates, Adnam Imeri and Jennifer Allouche, lauréats du programme financier ATIGE, create their research teams working on important subjects in genomics and innovative biotherapies.
Discover
Launched in late 2023 as part of the France 2030 plan, the PEPR "Biotherapies and Biomanufacturing" program seeks to place France as the spearhead of the key sector of biodrugs. Three of the program's priority projects are headed by Genopole laboratories.
Discover
Genopole is making available to the Île-de-France scientific community an Experimental Irradiation Platform equipped with a state of the art generator
Discover
Felome will begin the commercialization of a service offering genetic analyses for companion cats, to reveal their predispositions to over 50 diseases, identify their main physical traits, and their similarities with 14 types of breeds.
Discover
Three Gene.iO whiz kids, Alga Biologics, Fungu'it and Alt Biotech, rewarded for their innovations. Alga Biologics was among the 35 start-ups included in the French Blue Tech Index. Fungu'it and Alt Biotech, were selected to participate in 212 Founders, a start-up accompaniment and financing program by CDG Invest.
Discover
The international synthetic biology competition iGEM celebrated its 20th anniversary. From across the globe, the event drew more than 7,000 students in 400 teams from 66 countries. Genopole was there, among other actors in synthetic biology, to present the biocluster's advantages at its stand, and support the 17 students of the Évry Paris-Saclay team and their outstanding project, OptoGenEYEsis.
Discover
Genopole sent a team to Japan and South Korea to present itself and several of its accompanied businesses to major pharmaceutical corporations, investors and Asian bioclusters curious about biotechnological innovations and open to international partnerships.
Discover
passes a milestone in structure prediction for RNA complexes, key players in cell biology.
Discover
The IBISC laboratory has developed IRSOM2, an unprecedented bioinformatics tool for the prediction of bifunctional RNA, a relatively recently discovered class of RNA showing both an ability to code for proteins and an ability to perform biological roles.
Discover
